FINWIRES · TerminalLIVE
FINWIRES

SHE:300765

6 stories mentioning SHE:300765Updated 1d ago

Every FINWIRES story that references SHE:300765, newest first.

Asia

CSPC Innovation Pharma Subsidiary Gets FDA Clinical Trial Approval for CRB-701 Cancer Drug; Shares Slide 4%

CSPC Innovation Pharmaceutical (SHE:300765) subsidiary CSPC Jushi Biopharmaceutical received U.S. Food and Drug Administration clinical trial approval for its CRB-701 drug, according to a Wednesday after-hours filing with the Shenzhen Stock Exchange.The drug received approval for its TEMPO-1 randomized controlled clinical trial for the drug targeting Nectin-4, an antigen expressed in urothelial carcinoma as well as in cervical cancer and head and neck squamous cell carcinoma.Shares fell 4% during afternoon trading on Thursday.

SHE:300765
Asia

CSPC Innovation Pharmaceutical Receives China Approval for SYS6043 Clinical Trial; Shares Slide 4%

CSPC Innovation Pharmaceutical (SHE:300765) subsidiary Jushi Biopharmaceutical received approval from China's National Medical Products Administration for the phase 3 trial of its self-developed SYS6043 drug, according to a Thursday after-hours filing with the Shanghai Stock Exchange.SYS6043 is an antibody-drug conjugate that targets B7-H3 and releases a small molecule toxin to kill tumor cells, the company said in its filing.The trial will evaluate the response in patients with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.Shares in the drug company fell 4% during afternoon trading on Friday.

SHE:300765
Asia

CSPC Innovation Unit Starts Phase III Lung Cancer Drug Trial

CSPC Innovation Pharmaceutical (SHE:300765) subsidiary CSPC Jushi Biopharmaceutical has launched a Phase III clinical trial for its cancer therapy, SYS6010, according to a Shenzhen Stock Exchange filing on Wednesday.The trial targets patients with resected stage II-IIIB driver gene-negative non-small cell lung cancer who did not achieve a major pathological response after previous treatment.SYS6010 is a novel antibody-drug conjugate approved by China's National Medical Products Administration in June.

SHE:300765
Asia

CSPC Innovation Pharmaceutical Updates Hong Kong Listing Application

CSPC Innovation Pharmaceutical (SHE:300765) on June 18 updated its H-share listing application with the Hong Kong Stock Exchange, according to a Monday filing with the Shenzhen bourse.The pharmaceutical company initially filed its application on Dec. 10, 2025.Shares of CSPC Innovation Pharmaceutical rose nearly 1% in recent trade.

Hang SengSHE:300765
Asia

CSPC Innovation Pharmaceutical Subsidiary Gets Regulatory Nod for Cancer Drug Trial

CSPC Innovation Pharmaceutical (SHE:300765) unit CSPC Jushi Biopharmaceutical obtained the approval of China's medical products administrator to conduct clinical trials for SYS6041 in combination therapy for ovarian cancer.The potential indications for SYS6041 include solid tumors such as gynecological tumors and lung cancer, according to a Tuesday filing with the Shenzhen bourse.Shares of the pharmaceutical company closed 4% lower Tuesday.

SHE:300765
Asia

CSPC Innovation Pharma Gets China Nod for Psoriasis Drug

CSPC Innovation Pharmaceutical (SHE:300765, HKG:1093) received drug registration from China's medical products administrator for ustekinumab injection.The drug, branded as Enyike, is used to treat moderate to severe plaque psoriasis, according to Friday filings with the Shenzhen and Hong Kong bourses.

HKG:1093SHE:300765

Track with the FINWIRES app suite

FolioX
FolioX
Track SHE:300765 in your portfolio
WheelAI
WheelAI
Analyze SHE:300765 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHE:300765